# In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment

> **NCT07075757** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 20 (estimated)

## Conditions studied

- Brain Arteriovenous Malformations

## Interventions

- **DRUG:** Single in situ intra-arterial injection of bevacizumab

## Key facts

- **NCT ID:** NCT07075757
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07075757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07075757, "In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07075757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*